Stock 6996 ANTENGENE CORPORATION LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Company Antengene Corporation Limited

Equities

6996

KYG039571008

Biotechnology & Medical Research

Delayed Hong Kong S.E.
Other stock markets
 11:28:30 2024-04-24 pm EDT 		5-day change 1st Jan Change
0.86 HKD -1.15% Intraday chart for Antengene Corporation Limited 0.00% -57.00%
Mar. 22 Antengene Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 20 Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study CI

Business Summary

Antengene Corporation Limited is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.

Number of employees: 201

Sales per Business

HKD in Million2021Weight2022Weight Delta
Pharmaceutical Products
100.0 %
35 100.0 % 186 100.0 % +437.07%

Sales per region

HKD in Million2021Weight2022Weight Delta
Greater China
96.7 %
34 99.2 % 180 96.7 % +423.75%
Other Countries/Region
3.3 %
0 0.8 % 6 3.3 % +2,034.48%

Managers

Managers TitleAgeSince
Jian Ming Mei CEO
 Chief Executive Officer 58 18-08-27
Donald Andrew Lung DFI
 Director of Finance/CFO 42 -
Xiao-Jing Zhang CTO
 Chief Tech/Sci/R&D Officer - 22-12-15
Bo Shan CTO
 Chief Tech/Sci/R&D Officer - -
Yiteng Liu COO
 Chief Operating Officer 40 18-11-01
John F. Chin BRD
 Director/Board Member 58 20-08-17
Yang Cao SEC
 Corporate Secretary 34 20-08-17
Dirk Hoenemann PRN
 Corporate Officer/Principal - -
Jasmine Sun PRN
 Corporate Officer/Principal - -
Thomas Karalis PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Rafael Fonseca BRD
 Director/Board Member 57 23-04-13
Jian Ming Mei CEO
 Chief Executive Officer 58 18-08-27
Yiteng Liu COO
 Chief Operating Officer 40 18-11-01
John F. Chin BRD
 Director/Board Member 58 20-08-17
Jing Qian BRD
 Director/Board Member 48 20-11-08
Sheng Tang BRD
 Director/Board Member 40 20-11-08
Donald Andrew Lung DFI
 Director of Finance/CFO 42 -
Kan Chen BRD
 Director/Board Member 42 21-03-25

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 674,888,744 360,149,776 ( 53.36 %) 0 53.36 %

Shareholders

NameEquities%Valuation
Jian Ming Mei
26.07 %
175,927,994 26.07 % 22 M $
The Core Trust Co., Ltd.
9.448 %
63,760,332 9.448 % 8 M $
Fountainvest Partners (Asia) Ltd.
6.863 %
46,314,396 6.863 % 6 M $
Qiming Venture Partners Ltd.
5.952 %
40,170,442 5.952 % 5 M $
Fidelity Management & Research Co. LLC
3.001 %
20,251,939 3.001 % 3 M $
Fidelity Management & Research (Hong Kong) Ltd.
1.319 %
8,904,211 1.319 % 1 M $
Bosera Asset Management Co., Ltd.
0.5782 %
3,902,000 0.5782 % 498 559 $
Fidelity Management & Research (Japan) Ltd.
0.5448 %
3,676,500 0.5448 % 469 746 $
John F. Chin
0.2705 %
1,825,496 0.2705 % 233 244 $
Dimensional Fund Advisors Ltd.
0.008898 %
60,053 0.008898 % 7 673 $

Company contact information

Antengene Corp. Ltd.

Zhongshan SOHO Plaza 1065 West Zhongshan Road

200366, Suzhou

+

http://www.antengene.com
address Antengene Corporation Limited(6996)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Antengene Corporation Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8049 CNY
Average target price
1.666 CNY
Spread / Average Target
+107.06%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANTENGENE CORPORATION LIMITED Stock Antengene Corporation Limited
-56.50% 73.2M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.5B
ARGENX SE Stock argenx SE
+1.86% 22.19B
BIONTECH SE Stock BioNTech SE
-16.53% 21.33B
GENMAB A/S Stock Genmab A/S
-8.49% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 14.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 14.09B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 10.99B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6996 Stock
  4. Company Antengene Corporation Limited